Island Pharmaceuticals Limited
Island Pharmaceuticals Limited
Your view on ILA.AX
Overview
What the company does, where it operates, and who runs it.
About Island Pharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Charles Foster
- Headquarters
- 117 Camberwell Road, Hawthorn East, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Charles Foster
- Headquarters
- 117 Camberwell Road, Hawthorn East, VIC, AU
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101, is currently under development for both preventing and treating dengue fever and other illnesses transmitted by mosquitoes. The company participates in various strategic collaborations, including a research partnership with Monash University to evaluate known molecules against host targets, and a research and development alliance with Griffith University aimed at screening for active antiviral compounds through a systematic repurposing approach. Additionally, Island Pharmaceuticals has a research agreement with Compounds Australia, providing access to an extensive drug library containing roughly 4,500 molecules for potential drug repurposing and pipeline enhancement. In anticipation of its ISLA-101 Phase II clinical study, the company has also established a cooperative research and development pact with the U.S. Army. Other key agreements include a supply contract with Catalent for the production of Fenretinide softgels for individuals participating in dengue fever trials, and the entitlement to reference the National Cancer Institute's Investigational New Drug (IND) application for ISLA-101. The company, founded in 2017, is based in Camberwell, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Island Pharmaceuticals Limited, and the rating behind it. ILA.AX last traded at AUD 0.45; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Island Pharmaceuticals Limited. Starting points for Island Pharmaceuticals Limited: EPS -AUD 0.03, beta 0.12 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Island Pharmaceuticals Limited. Island Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Island Pharmaceuticals Limited. Trailing twelve-month EPS for Island Pharmaceuticals Limited stands at -AUD 0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Island Pharmaceuticals Limited. Island Pharmaceuticals Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Island Pharmaceuticals Limited valued side by side against its closest peers. Island Pharmaceuticals Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Island Pharmaceuticals Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Island Pharmaceuticals Limited executives and directors. Shares of Island Pharmaceuticals Limited have traded between AUD 0.17 and AUD 0.63 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Island Pharmaceuticals Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Island Pharmaceuticals Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Island Pharmaceuticals Limited. Coverage tracks Island Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.